The demand for spinal pain treatment options in the United States is expected to rise at a CAGR of 10.6% during the forecast period. Total revenue in the country is projected to increase from US$ 3,962.7 million in 2023 to US$ 10,962.7 million by 2033. In 2022, overall sales totaled around US$ 3,635.2 million in the United States.
Key Highlights
Revenue in the United States is projected to expand around 2.8X through 2033, amid a 3.2% increase in expected CAGR compared to the historical one. This is attributable to the growing prevalence of back pain and rising patient spending on spine pain management.
As per the latest United States spine pain industry analysis and trends, the spinal non-fusion segment is expected to hold a dominant value share of around 36.8% in 2033. This is attributable to the rising popularity of spinal non-fusion surgery. This type of surgery is gaining momentum due to its benefits, including less pain, fast recovery time, reduced risk of complications, and preservation of spinal motion.
| Attributes | Key Insights |
|---|---|
| United States Spine Pain Business Revenue in 2022 | US$ 3,635.2 million |
| Estimated Value in 2023 | US$ 3,962.7 million |
| Projected Value in 2033 | US$ 10,962.7 million |
| Value-based CAGR (2023 to 2033) | 10.6% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The spine pain business encompasses the analysis of multiple spinal pains and their respective therapeutic approaches aimed at addressing unmet needs and improving the quality of life for individuals. It is expected to flourish during the forecast period due to several factors, including the rising prevalence of back pain.
The growing prevalence of back pain in the United States is a prominent factor expected to drive demand during the forecast period. This is because patients suffering from back pain often opt for different treatments.
In recent years, there has been a spike in cases of back pain across the United States due to factors such as sedentary lifestyles, weight gain, and poor posture. As per the National Center for Health Statistics, around 39.0% of adults suffered from back pain in 2019. This dramatic rise in back pain is expected to boost sales growth in the United States.
Principal Consultant
Spine pain product sales in the United States increased at a CAGR of 7.4% between 2018 and 2022. Over the assessment period, the United States is poised to exhibit a CAGR of 10.6%.
| Historical CAGR (2018 to 2022) | 7.4% |
|---|---|
| Forecast CAGR (2023 to 2033) | 10.6% |
The demand for patient-centric care is of utmost importance and a transformative trend in the spine pain business. It is mainly driven by a shift in patient expectations and recognition of the importance of tailoring care to individual needs. This trend reflects the growing desire of patients to play an active role in their healthcare decisions and to receive treatments that align with their unique circumstances, preferences, and lifestyles.
Patients are increasingly looking for treatments that recognize their unique pain experiences, taking into account elements, including pain intensity, impact on everyday life, and individual pain thresholds. This demand encourages healthcare providers to have meaningful dialogues with patients, listen carefully to their concerns, and collaborate to build treatment programs that represent their individual pain profiles.
The increasing need for patient-centered care in the spine pain business represents a fundamental shift in the healthcare landscape. This is expected to boost revenue in the United States through 2033.
Mobile apps designed for spine pain management can serve as versatile tools that empower patients to participate actively in their treatment journey. These apps can provide personalized exercise regimens, pain-tracking functionalities, and educational resources, allowing patients to better understand their condition and adhere to recommended therapies.
By engaging patients in their care, these apps foster a sense of ownership and accountability. They potentially lead to more effective pain management and a reduced reliance on acute interventions.
Multidisciplinary back pain apps such as the Kaia app for use on mobile devices have shown greater effectiveness than physiotherapy in combination with online education in treating patients with lower back pain. These results support those of another large study of more than 10,000 adults that showed a digital care program available through a mobile app resulted in a significant positive relationship between engagement and pain reduction.
Interdisciplinary collaboration represents a transformative opportunity in the spine pain business and a shift toward comprehensive & patient-centered care. In a landscape where spine pain often extends beyond physical discomfort to encompass psychological and emotional burdens, collaborative care models bring together experts from diverse fields.
Collaborative care models can also bring together surgeons, pain management specialists, physiotherapists, and psychologists to offer holistic treatment approaches that address the multifaceted nature of spine pain. This is set to bode well for the target business in the United States.
The interdisciplinary collaboration lies in the recognition that spine pain isn't solely a mechanical issue. It encompasses physiological, psychological, and even social dimensions.
Orthopedic spine surgeons in the United States contribute their expertise in diagnosing structural issues and performing necessary surgical interventions. Pain management specialists would play a crucial role in providing effective pain relief strategies, ensuring that patients experience comfort while undergoing treatment.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Patients who lack comprehensive health insurance coverage or have high deductibles can find themselves unable to afford the necessary interventions for their spine pain. This finanacial strain can compel patients to delay or altogether forgo treatments, leading to exacerbated pain, reduced quality of life, and an increased potential for long-term complications. Consequently, the pool of potential patients who can benefit from these treatments shrinks, adversely affecting the industry’s expansion.
The economic burden extends beyond individuals to healthcare systems and insurers. The high costs of spine pain treatments strain healthcare budgets and contribute to rising healthcare expenditures. This financial stress can result in tougher decisions on reimbursement policies and coverage limitations, further restricting patients' options for receiving timely and appropriate care.
Growth Outlook by Key State
| States | Value-based CAGR |
|---|---|
| South Carolina | 9.9% |
| Florida | 11.3% |
| Virginia | 10.7% |
| North Carolina | 10.4% |
| California | 11.7% |
Sales in South Carolina are expected to rise at 9.9% CAGR during the forecast period. This is attributable to the rising prevalence of spine-related issues and the presence of well-established healthcare infrastructure.
The high prevalence of obesity in South Carolina is closely related to the increasing incidence of spine-related issues. As there are several healthcare facilities in South Carolina, such as hospitals, clinics, and specialist centers, these institutions offer spine pain management services. These are estimated to improve access to care and contribute to sales growth.
The state boasts orthopedic and neurosurgical experts who specialize in spine pain treatment and surgery. This expertise is expected to attract patients seeking advanced care, particularly for complex spine conditions.
Demand in Florida is projected to increase at a CAGR of 11.3% during the assessment period. This can be attributed to the presence of several specialized spine pain treatment centers in the state and growing cases of spine diseases.
Florida hosts several specialized spine pain treatment centers, drawing patients from all over the United States. These centers offer a wide range of services, including surgical and non-surgical interventions.
Florida's focus on pain management services has led to the establishment of specialized pain clinics offering interventional and medication-based pain relief solutions. The growing inclination of patients to opt for treatments in these clinics will likely boost revenue in Florida.
The below section highlights the prediction for the spinal non fusion segment, which is expected to hold a dominant share based on product type. It is expected to exhibit a CAGR of 10.5% through 2033.
Based on pain type, the thoracolumbar pain segment is anticipated to lead the United States. It will likely progress at 8.9% CAGR during the assessment period.
In terms of end users, the hospital segment is set to generate significant revenue in the United States. It is poised to thrive at a CAGR of 7.1% between 2023 and 2023.
Growth Outlook by Key Product Type
| Product | Value-based CAGR |
|---|---|
| Spinal Fusion | 7.5% |
| Spinal Non Fusion | 10.5% |
| Vertebral Body Replacement Systems | 10.6% |
| Spinal Cord Stimulation | 15.5% |
| Transcutaneous Electrical Neuromuscular Stimulation (TENS) | 13.0% |
| Spinal Epidural Injection | 13.1% |
As per the latest United States spine pain industry analysis, the spinal non-fusion segment is projected to thrive at a CAGR of 10.5% during the forecast period. By 2033, the target segment is set to reach US$ 4,033.3 million.
The rising usage of spinal non-fusion devices to treat spinal disorders without permanently connecting or fusing vertebrae together is expected to boost the segment. These medical implants or devices are set to be used to treat disorders, such as spinal instability, discomfort, and disc problems while permitting natural movement of the spine.
A handful of examples of spine non-fusion devices include facet arthroplasty devices, annulus repair devices, artificial disc replacement systems, nuclear disc prostheses, interspinous process decompression (IPD) devices, and pedicle screw-based dynamic stabilization systems.
Growth Outlook by Pain Type
| Pain Type | Value-based CAGR |
|---|---|
| Cervical Pain | 12.2% |
| Thoracolumbar Pain | 8.9% |
| Lumbar Pain | 11.0% |
| Sciatic Pain | 10.7% |
Based on pain type, the thoracolumbar pain segment is expected to progress at a CAGR of 8.9% during the assessment period. It will likely total a valuation of US$ 1,554.8 million in 2023.
Patients in the United States often grapple with thoracolumbar pain, which resides in the mid-back where the thoracic and lumbar spine meet. This discomfort arises from irritation of the thoracolumbar facet joints. When it comes to managing or resolving this pain, they have a range of treatment options to consider.
Management of thoracolumbar pain frequently involves physical therapy and rehabilitation. The demand for these services has led to an expansion of physical therapy clinics and rehabilitation facilities, which contributes to the sales growth in the United States.
The treatment often includes pain medications, nerve blocks, and other interventional therapies. These pharmaceutical and medical interventions are expected to drive growth in the pharmaceutical and medical device sectors, thereby boosting revenue in the United States.
Growth Outlook by Key End User
| Application | Value-based CAGR |
|---|---|
| Hospitals | 7.1% |
| Specialty Clinic | 11.5% |
| Ambulatory Surgical Centers | 14.6% |
The hospital segment is anticipated to expand at 7.1% CAGR over the forecast period. It is predicted to total a valuation of US$ 1,925.2 million by 2033.
Hospitals are typically located in convenient and accessible locations, making it easier for patients to seek care for spine pain without the need for a hospital visit. This accessibility encourages more people to access treatment, ultimately expanding the patient base in hospitals.
The ambulatory care center segment is expected to witness a higher CAGR of 14.6% through 2033. Ambulatory care centers often offer shorter wait times compared to traditional hospitals. Patients with spine pain can receive timely evaluations, diagnostic tests, and treatment, leading to faster relief and improved patient satisfaction.
Key players are focusing on introducing novel solutions for back pain. Strategic partnerships are a priority for leading United States-based spine pain solution providers. Several players are also investing in research and development as well as implementing strategies, including acquisitions, mergers, and collaborations, to solidify their positions.
Recent Developments in Spine Pain Therapy Business
| Attribute | Details |
|---|---|
| Estimated Size (2023) | US$ 3,962.7 million |
| Projected Value (2033) | US$ 10,962.7 million |
| Anticipated Growth Rate (2023 to 2033) | 10.6% |
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Industry Analysis | Value (US$ million) |
| Key Regions Covered | Northeast; Midwest; Southeast; Southwest; West |
| Key States Covered | New York, New Jersey, Massachusetts, Rest of North East, Minnesota, Wisconsin, Rest of Midwest, North Carolina, South Carolina, Florida, Virginia, Rest of Southeast, Louisiana, Oklahoma, Texas, Rest of Southeast, Washington, California, New Mexico, Rest of West |
| Key Segments Covered | Product Type, Pain Type, End User, and Region |
| Key Companies Profiled | Zimmer, Inc. (ZimVie Inc.); Medtronic; Johnson & Johnson; Stryker Corporation; Abbott Laboratories; Boston Scientific Corporation; B Braun (Aesculap, Inc.); Becton, Dickinson and Company; Globus Medical; Alphatec Spine, Inc.; Nevro Corp; NuVasive, Inc.; Orthofix US LLC.; Surgalign Spine Technologies, Inc.; Precision Spine, Inc. |
| Report Coverage | Sales Forecast, Competition Intelligence, Key Dynamics and Challenges, Strategic Growth Initiatives |
Revenue in the United States is set to reach US$ 3,962.7 million by 2023.
Sales in the United States are expected to total US$ 10,962.7 million by 2033.
Demand in the United States is set to rise at 10.6% CAGR through 2033.
The spinal non-fusion segment held around 37.2% share in 2022.
Sales in the United States increased at 7.4% CAGR from 2018 to 2022.
The Southeast region accounted for 36.6% value share in 2022.
About 29.9% of people aged 18 and older suffered from lower back pain in 2018.
Around US$ 50 billion is spent by people in the United States on back pain each year.
1. Executive Summary
1.1. United States Industry Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Overview
2.1. Coverage / Taxonomy
2.2. Product Definition / Scope / Limitations
2.3. Inclusions & Exclusions
3. Key Trends
3.1. Key Trends Impacting Sales
3.2. Product Innovation / Development Trends
4. Value Added Insights
4.1. Product Assessment
4.1.1. Product Adoption Analysis
4.1.2. Product USP's/Features Analysis
4.1.3. Recent Product Launches and Innovations
4.1.4. Product Matrix Analysis
4.2. Number of Procedures
4.3. Regulatory Landscape
4.4. Reimbursement Scenario
4.4.1. Reimbursement Guidelines
4.4.2. Reimbursement Codes
4.4.3. Payer Mix Analysis
4.5. PESTLE Analysis
4.6. Porter’s Analysis
5. Background
5.1. Macro-Economic Factors
5.1.1. United States Healthcare Expenditure
5.1.2. United States R&D Funding
5.1.3. United States Medical Device Industry Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Obesity Epidemic
5.2.2. Technological Advancements
5.2.3. Regulatory Changes
5.2.4. Telemedicine Adoption
5.2.5. Pain Management Solutions
5.2.6. Posture and Lifestyle Changes
5.2.7. Economic Factors
5.2.8. Competition and Key Players
5.2.9. Healthcare Infrastructure
5.3. Key Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Volume (Units) Analysis 2018 to 2022 and Forecast, 2023 to 2033
6.1. Historical Volume (Units) Analysis, 2018 to 2022
6.2. Current and Future Volume (Units) Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
7. Demand Pricing Analysis
7.1. Average Pricing Analysis Benchmark
7.2. Pricing Break-up
7.2.1. Manufacturer Level Pricing
7.2.2. Distributor Level Pricing
7.3. Pricing Assumptions
8. Demand (in Value or Size in US$ million) Analysis 2018 to 2022 and Forecast, 2023 to 2033
8.1. Revenue Opportunity Scenario
8.2. Historical Value (US$ million) Analysis, 2018 to 2022
8.3. Current and Future Value (US$ million) Projections, 2023 to 2033
8.3.1. Y-o-Y Growth Trend Analysis
8.3.2. Absolute $ Opportunity Analysis
9. Demand Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type
9.1. Introduction / Key Findings
9.2. Historical Size (US$ million) and Volume (Units) Analysis by Product Type, 2018 to 2022
9.3. Current and Future Size (US$ million) and Volume (Units) Analysis and Forecast by Product Type, 2023 to 2033
9.3.1. Spinal Fusion
9.3.1.1. Interbody Devices
9.3.1.2. Pedicle Screw Systems
9.3.1.3. Spinal Plating Systems
9.3.2. Spinal Non-fusion
9.3.2.1. Annulus Repair Devices
9.3.2.2. Artificial Disc Replacement Systems
9.3.2.3. Interspinous Process Decompression (IPD) Devices
9.3.2.4. Pedicle Screw-based Dynamic Stabilization Systems
9.3.3. Vertebral Body Replacement Systems
9.3.4. Spinal Cord Stimulation
9.3.5. Transcutaneous Electrical Neuromuscular Stimulation (TENS)
9.3.6. Spinal Epidural Injection
9.4. Attractiveness Analysis by Product Type
10. Demand Analysis 2018 to 2022 and Forecast 2023 to 2033, By Pain Type
10.1. Introduction / Key Findings
10.2. Historical Size (US$ million) Analysis by Pain Type, 2018 to 2022
10.3. Current and Future Size (US$ million) Analysis and Forecast by Pain Type, 2023 to 2033
10.3.1. Cervical Pain
10.3.1.1. Arm Pain
10.3.2. Thoracolumbar Pain
10.3.2.1. Arm Pain
10.3.2.2. Leg Pain
10.3.3. Lumbar Pain
10.3.3.1. Leg Pain
10.3.4. Sciatic Pain
10.3.4.1. Leg Pain
10.4. Attractiveness Analysis by Pain Type
11. Demand Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
11.1. Introduction / Key Findings
11.2. Historical Size (US$ million) Analysis by End User, 2018 to 2022
11.3. Current and Future Size (US$ million) Analysis and Forecast By End User, 2023 to 2033
11.3.1. Hospitals
11.3.2. Specialty Clinics
11.3.3. Ambulatory Surgical Centers
11.4. Attractiveness Analysis by End User
12. Demand Analysis: Cross-Sectional Analysis - Pain Type Vs Product Type
12.1. Historical Size (US$ million) Product Type Vs Pain Type, 2018 to 2022
12.2. Current and Future Size (US$ million) Analysis and Forecast Product Type Vs Pain Type 2023 to 2033
12.2.1. Cervical Pain
12.2.1.1. Spinal Fusion
12.2.1.1.1. Interbody Devices
12.2.1.1.2. Pedicle Screw Systems
12.2.1.1.3. Spinal Plating Systems
12.2.1.2. Spinal Non-Fusion
12.2.1.2.1. Annulus Repair Devices
12.2.1.2.2. Artificial Disc Replacement Systems
12.2.1.2.3. Interspinous Process Decompression (IPD) Devices
12.2.1.2.4. Pedicle Screw-Based Dynamic Stabilization Systems
12.2.1.3. Vertebral Body Replacement Systems
12.2.1.4. Spinal Cord Stimulation
12.2.1.5. Transcutaneous Electrical Neuromuscular Stimulation (TENS)
12.2.1.6. Spinal Epidural Injection
12.2.2. Thoracolumbar Pain
12.2.2.1. Spinal Fusion
12.2.2.1.1. Interbody Devices
12.2.2.1.2. Pedicle Screw Systems
12.2.2.1.3. Spinal Plating Systems
12.2.2.2. Spinal Non-Fusion
12.2.2.2.1. Annulus Repair Devices
12.2.2.2.2. Artificial Disc Replacement Systems
12.2.2.2.3. Interspinous Process Decompression (IPD) Devices
12.2.2.2.4. Pedicle Screw-Based Dynamic Stabilization Systems
12.2.2.3. Vertebral Body Replacement Systems
12.2.2.4. Spinal Cord Stimulation
12.2.2.5. Transcutaneous Electrical Neuromuscular Stimulation (TENS)
12.2.2.6. Spinal Epidural Injection
12.2.3. Lumbar Pain
12.2.3.1. Spinal Fusion
12.2.3.1.1. Interbody Devices
12.2.3.1.2. Pedicle Screw Systems
12.2.3.1.3. Spinal Plating Systems
12.2.3.2. Spinal Non-Fusion
12.2.3.2.1. Annulus Repair Devices
12.2.3.2.2. Artificial Disc Replacement Systems
12.2.3.2.3. Interspinous Process Decompression (IPD) Devices
12.2.3.2.4. Pedicle Screw-Based Dynamic Stabilization Systems
12.2.3.3. Vertebral Body Replacement Systems
12.2.3.4. Spinal Cord Stimulation
12.2.3.5. Transcutaneous Electrical Neuromuscular Stimulation (TENS)
12.2.3.6. Spinal Epidural Injection
12.2.4. Sciatic Pain
12.2.4.1. Spinal Fusion
12.2.4.1.1. Interbody Devices
12.2.4.1.2. Pedicle Screw Systems
12.2.4.1.3. Spinal Plating Systems
12.2.4.2. Spinal Non-Fusion
12.2.4.2.1. Annulus Repair Devices
12.2.4.2.2. Artificial Disc Replacement Systems
12.2.4.2.3. Interspinous Process Decompression (IPD) Devices
12.2.4.2.4. Pedicle Screw-Based Dynamic Stabilization Systems
12.2.4.3. Vertebral Body Replacement Systems
12.2.4.4. Spinal Cord Stimulation
12.2.4.5. Transcutaneous Electrical Neuromuscular Stimulation (TENS)
12.2.4.6. Spinal Epidural Injection
13. United States Demand Analysis 2018 to 2022 and Forecast 2023 to 2033, by Region
13.1. Introduction
13.2. Historical Size (US$ million) and Volume (Units) Analysis, By Region, 2018 to 2022
13.3. Current and Future Size (US$ million) and Volume (Units) Analysis and Forecast By Region, 2023 to 2033
13.3.1. Northeast
13.3.2. Midwest
13.3.3. Southeast
13.3.4. Southwest
13.3.5. West
13.4. Attractiveness Analysis by Region
14. Northeast Demand Analysis 2018 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Size (US$ million) and Volume (Units) Trend Analysis by Taxonomy, 2018 to 2022
14.3. Current and Future Size (US$ million) and Volume (Units) Analysis and Forecast By Taxonomy, 2023 to 2033
14.3.1. By States
14.3.1.1. New York
14.3.1.2. New Jersey
14.3.1.3. Massachusetts
14.3.1.4. Rest of North East
14.3.2. By Product Type
14.3.3. By Pain Type
14.3.4. By End User
14.4. Attractiveness Analysis
14.4.1. By States
14.4.2. By Product Type
14.4.3. By Pain Type
14.4.4. By End User
14.5. Key Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
14.7. State Level Analysis & Forecast
14.7.1. New York Demand Analysis
14.7.1.1. Introduction
14.7.1.2. Demand Analysis and Forecast by Taxonomy
14.7.1.2.1. By Product Type
14.7.1.2.2. By Pain Type
14.7.1.2.3. By End User
14.7.2. New Jersey Demand Analysis
14.7.2.1. Introduction
14.7.2.2. Demand Analysis and Forecast by Taxonomy
14.7.2.2.1. By Product Type
14.7.2.2.2. By Pain Type
14.7.2.2.3. By End User
14.7.3. Massachusetts Demand Analysis
14.7.3.1. Introduction
14.7.3.2. Demand Analysis and Forecast by Taxonomy
14.7.3.2.1. By Product Type
14.7.3.2.2. By Pain Type
14.7.3.2.3. By End User
15. Midwest Demand Analysis 2018 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Size (US$ million) and Volume (Units) Trend Analysis by Taxonomy, 2018 to 2022
15.3. Current and Future Size (US$ million) and Volume (Units) Analysis and Forecast By Taxonomy, 2023 to 2033
15.3.1. By States
15.3.1.1. Minnesota
15.3.1.2. Wisconsin
15.3.1.3. Rest of Midwest
15.3.2. By Product Type
15.3.3. By Pain Type
15.3.4. By End User
15.4. Attractiveness Analysis
15.4.1. By States
15.4.2. By Product Type
15.4.3. By Pain Type
15.4.4. By End User
15.5. States Level Analysis & Forecast
15.5.1. Minnesota Demand Analysis
15.5.1.1. Introduction
15.5.1.2. Demand Analysis and Forecast by Taxonomy
15.5.1.2.1. By Product Type
15.5.1.2.2. By Pain Type
15.5.1.2.3. By End User
15.5.2. Wisconsin Demand Analysis
15.5.2.1. Introduction
15.5.2.2. Demand Analysis and Forecast by Taxonomy
15.5.2.2.1. By Product Type
15.5.2.2.2. By Pain Type
15.5.2.2.3. By End User
16. Southeast Demand Analysis 2018 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Size (US$ million) and Volume (Units) Trend Analysis by Taxonomy, 2018 to 2022
16.3. Current and Future Size (US$ million) and Volume (Units) Analysis and Forecast By Taxonomy, 2023 to 2033
16.3.1. By States
16.3.1.1. North Carolina
16.3.1.2. South Carolina
16.3.1.3. Florida
16.3.1.4. Virginia
16.3.1.5. Rest of Southeast
16.3.2. By Product Type
16.3.3. By Pain Type
16.3.4. By End User
16.4. Attractiveness Analysis
16.4.1. By States
16.4.2. By Product Type
16.4.3. By Pain Type
16.4.4. By End User
16.5. Drivers and Restraints - Impact Analysis
16.6. State Level Analysis & Forecast
16.6.1. North Carolina Demand Analysis
16.6.1.1. Introduction
16.6.1.2. Demand Analysis and Forecast by Taxonomy
16.6.1.2.1. By Product Type
16.6.1.2.2. By Pain Type
16.6.1.2.3. By End User
16.6.2. South Carolina Demand Analysis
16.6.2.1. Introduction
16.6.2.2. Demand Analysis and Forecast by Taxonomy
16.6.2.2.1. By Product Type
16.6.2.2.2. By Pain Type
16.6.2.2.3. By End User
16.6.3. Florida Demand Analysis
16.6.3.1. Introduction
16.6.3.2. Demand Analysis and Forecast by Taxonomy
16.6.3.2.1. By Product Type
16.6.3.2.2. By Pain Type
16.6.3.2.3. By End User
16.6.4. Virginia Demand Analysis
16.6.4.1. Introduction
16.6.4.2. Demand Analysis and Forecast by Taxonomy
16.6.4.2.1. By Product Type
16.6.4.2.2. By Pain Type
16.6.4.2.3. By End User
17. Southwest Demand Analysis 2018 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Size (US$ million) and Volume (Units) Trend Analysis by Taxonomy, 2018 to 2022
17.3. Current and Future Size (US$ million) and Volume (Units) Analysis and Forecast By Taxonomy, 2023 to 2033
17.3.1. By States
17.3.1.1. Louisiana
17.3.1.2. Oklahoma
17.3.1.3. Texas
17.3.1.4. Rest of Southwest
17.3.2. By Product Type
17.3.3. By Pain Type
17.3.4. By End User
17.4. Attractiveness Analysis
17.4.1. By States
17.4.2. By Product Type
17.4.3. By Pain Type
17.4.4. By End User
17.5. Drivers and Restraints - Impact Analysis
17.6. State Level Analysis & Forecast
17.6.1. Louisiana Demand Analysis
17.6.1.1. Introduction
17.6.1.2. Demand Analysis and Forecast by Taxonomy
17.6.1.2.1. By Product Type
17.6.1.2.2. By Pain Type
17.6.1.2.3. By End User
17.6.2. Oklahoma Demand Analysis
17.6.2.1. Introduction
17.6.2.2. Demand Analysis and Forecast by Taxonomy
17.6.2.2.1. By Product Type
17.6.2.2.2. By Pain Type
17.6.2.2.3. By End User
17.6.3. Texas Demand Analysis
17.6.3.1. Introduction
17.6.3.2. Demand Analysis and Forecast by Taxonomy
17.6.3.2.1. By Product Type
17.6.3.2.2. By Pain Type
17.6.3.2.3. By End User
18. West Demand Analysis 2018 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Size (US$ million) and Volume (Units) Trend Analysis by Taxonomy, 2018 to 2022
18.3. Current and Future Size (US$ million) and Volume (Units) Analysis and Forecast By Taxonomy, 2023 to 2033
18.3.1. By States
18.3.1.1. Washington
18.3.1.2. California
18.3.1.3. New Mexico
18.3.1.4. Rest of West
18.3.2. By Product Type
18.3.3. By Pain Type
18.3.4. By End User
18.4. Attractiveness Analysis
18.4.1. By States
18.4.2. By Product Type
18.4.3. By Pain Type
18.4.4. By End User
18.5. Drivers and Restraints - Impact Analysis
18.6. State Level Analysis & Forecast
18.6.1. Washington Demand Analysis
18.6.1.1. Introduction
18.6.1.2. Demand Analysis and Forecast by Taxonomy
18.6.1.2.1. By Product Type
18.6.1.2.2. By Pain Type
18.6.1.2.3. By End User
18.6.2. California Demand Analysis
18.6.2.1. Introduction
18.6.2.2. Demand Analysis and Forecast by Taxonomy
18.6.2.2.1. By Product Type
18.6.2.2.2. By Pain Type
18.6.2.2.3. By End User
18.6.3. New Mexico Demand Analysis
18.6.3.1. Introduction
18.6.3.2. Demand Analysis and Forecast by Taxonomy
18.6.3.2.1. By Product Type
18.6.3.2.2. By Pain Type
18.6.3.2.3. By End User
19. Structure Analysis
19.1. Demand Analysis by Tier of Companies
19.2. Share Analysis of Top Players
20. Competition Analysis
20.1. Competition Benchmarking
20.2. Branding & Promotional Strategies by Key Players
20.3. Key Development Analysis
20.4. Competition Dashboard
20.5. Competition Deep Dive
20.5.1. ZimVie Inc.
20.5.1.1. Company Overview
20.5.1.2. Product Portfolio
20.5.1.3. Sales Footprint
20.5.1.4. Key Financials
20.5.1.5. SWOT Analysis
20.5.1.6. Key Developments
20.5.1.7. Strategy Overview
20.5.1.7.1. Channel Strategy
20.5.1.7.2. Business Strategy
20.5.1.7.3. Product Strategy
20.5.2. Medtronic
20.5.2.1. Company Overview
20.5.2.2. Product Portfolio
20.5.2.3. Sales Footprint
20.5.2.4. Key Financials
20.5.2.5. SWOT Analysis
20.5.2.6. Key Developments
20.5.2.7. Strategy Overview
20.5.3. Johnson & Johnson
20.5.3.1. Company Overview
20.5.3.2. Product Portfolio
20.5.3.3. Sales Footprint
20.5.3.4. Key Financials
20.5.3.5. SWOT Analysis
20.5.3.6. Key Developments
20.5.3.7. Strategy Overview
20.5.4. Stryker Corporation
20.5.4.1. Company Overview
20.5.4.2. Product Portfolio
20.5.4.3. Sales Footprint
20.5.4.4. Key Financials
20.5.4.5. SWOT Analysis
20.5.4.6. Key Developments
20.5.4.7. Strategy Overview
20.5.5. Abbott Laboratories
20.5.5.1. Company Overview
20.5.5.2. Product Portfolio
20.5.5.3. Sales Footprint
20.5.5.4. Key Financials
20.5.5.5. SWOT Analysis
20.5.5.6. Key Developments
20.5.5.7. Strategy Overview
20.5.6. Boston Scientific Corporation
20.5.6.1. Company Overview
20.5.6.2. Product Portfolio
20.5.6.3. Sales Footprint
20.5.6.4. Key Financials
20.5.6.5. SWOT Analysis
20.5.6.6. Key Developments
20.5.6.7. Strategy Overview
20.5.7. B Braun (Aesculap, Inc)
20.5.7.1. Company Overview
20.5.7.2. Product Portfolio
20.5.7.3. Sales Footprint
20.5.7.4. Key Financials
20.5.7.5. SWOT Analysis
20.5.7.6. Key Developments
20.5.7.7. Strategy Overview
20.5.8. Becton, Dickinson and Company
20.5.8.1. Company Overview
20.5.8.2. Product Portfolio
20.5.8.3. Sales Footprint
20.5.8.4. Key Financials
20.5.8.5. SWOT Analysis
20.5.8.6. Key Developments
20.5.8.7. Strategy Overview
20.5.9. Globus Medical
20.5.9.1. Company Overview
20.5.9.2. Product Portfolio
20.5.9.3. Sales Footprint
20.5.9.4. Key Financials
20.5.9.5. SWOT Analysis
20.5.9.6. Key Developments
20.5.9.7. Strategy Overview
20.5.10. Alphatec Spine, Inc.
20.5.10.1. Company Overview
20.5.10.2. Product Portfolio
20.5.10.3. Sales Footprint
20.5.10.4. Key Financials
20.5.10.5. SWOT Analysis
20.5.10.6. Key Developments
20.5.10.7. Strategy Overview
20.5.11. Nevro Corp
20.5.11.1. Company Overview
20.5.11.2. Product Portfolio
20.5.11.3. Sales Footprint
20.5.11.4. Key Financials
20.5.11.5. SWOT Analysis
20.5.11.6. Key Developments
20.5.11.7. Strategy Overview
20.5.12. NuVasive, Inc.
20.5.12.1. Company Overview
20.5.12.2. Product Portfolio
20.5.12.3. Sales Footprint
20.5.12.4. Key Financials
20.5.12.5. SWOT Analysis
20.5.12.6. Key Developments
20.5.12.7. Strategy Overview
20.5.13. Orthofix US LLC.
20.5.13.1. Company Overview
20.5.13.2. Product Portfolio
20.5.13.3. Sales Footprint
20.5.13.4. Key Financials
20.5.13.5. SWOT Analysis
20.5.13.6. Key Developments
20.5.13.7. Strategy Overview
20.5.14. Surgalign Spine Technologies, Inc.
20.5.14.1. Company Overview
20.5.14.2. Product Portfolio
20.5.14.3. Sales Footprint
20.5.14.4. Key Financials
20.5.14.5. SWOT Analysis
20.5.14.6. Key Developments
20.5.14.7. Strategy Overview
20.5.15. Precision Spine, Inc.
20.5.15.1. Company Overview
20.5.15.2. Product Portfolio
20.5.15.3. Sales Footprint
20.5.15.4. Key Financials
20.5.15.5. SWOT Analysis
20.5.15.6. Key Developments
20.5.15.7. Strategy Overview
21. Assumptions and Acronyms Used
22. Research Methodology
Explore Healthcare Insights
View Reports
Spine Pain Industry Analysis in United States
